Scientists Are Trying to Stop Pancreatic Cancer Before It Even Starts

A Deadly Disease, a Radical New Idea

Pancreatic cancer has long been one of medicine's most humbling adversaries. It is typically found late, spreads fast, and kills most of the people it touches. Its incidence is rising at a rate of up to 1% per year, projected to become the second-leading cause of cancer death by 2030, and despite advances in treatment, it carries a five-year survival rate of around 10%. But 2026 has brought a striking shift in how researchers think about the disease — not just how to treat it, but how to stop it before it fully forms.

With prospects for new treatments at an all-time high, researchers are now looking for ways to boost survival by treating the disease early — a strategy called interception, which is already being trialed for breast and skin cancers, among others. The idea is bold: identify people at high risk, find the earliest biological warning signs, and intervene before a tumor ever takes hold.

A Vaccine That Trains the Body to Fight Back Early

Using an "off-the-shelf" vaccine, researchers from Johns Hopkins Kimmel School of Medicine and Skip Viragh Center for Pancreatic Cancer have demonstrated, for the first time, the ability to generate an immune response targeting mutant KRAS in people who are at high risk for developing pancreatic cancer. The vaccine, called mKRAS-VAX, works by arming the immune system against the genetic mutation that drives the vast majority of cases. Mutations in the KRAS gene are the main oncogenic drivers in more than 90% of pancreatic ductal adenocarcinomas.

Twenty participants with a hereditary predisposition to pancreatic cancer and a pancreatic abnormality identified through imaging received the vaccine between April 2022 and February 2026, with four doses administered over 13 weeks. The results were encouraging. Vaccination elicited a significant mutant KRAS-specific T-cell response in 18 of 20 participants — 90% — and over a median follow-up of 16.5 months, no participants developed pancreatic cancer. Remarkably, 37% of participants had a reduction in the size of their pancreatic lesions, and five had complete regression of their lesions.

Attacking Precancerous Lesions Before They Become Tumors

The vaccine trial is part of a broader wave of interception science. In a separate and complementary line of research, a preclinical study published in March 2026 showed that precancerous cells in the pancreas can be eliminated before they have the chance to become tumors, with the experimental therapy nearly doubling survival in mouse models of pancreatic ductal adenocarcinoma compared to the same treatment given after cancer developed.

It was the first time scientists showed that a medical intervention could stop growth of pre-cancerous lesions in the pancreas before they develop into pancreatic cancer, providing strong evidence for the burgeoning field of cancer interception. Long-term interception in tumor-prone mice resulted in a median overall survival of more than one year, compared with less than five months in non-intercepted control mice. That kind of dramatic difference — in animals, at least — is exactly what motivates researchers to push toward human trials.

A Turning Point, With More Work Ahead

The interception strategy is gaining momentum alongside other breakthroughs in treatment. Revolution Medicines presented results in May 2026 from its Phase 3 clinical trial of 500 patients with metastatic pancreatic cancer, finding that a new drug called daraxonrasib nearly doubled overall survival from 6.7 months to 13.2 months compared to standard chemotherapy. Together, these advances paint a picture of a field that is finally, after decades of frustration, finding traction.

For people with a family history of the disease or a known genetic predisposition, the implications of interception research are personal and urgent. Currently, people with such hereditary risk "can only 'watch and wait' with regular surveillance," with options to proactively intercept disease progression "desperately needed." If vaccines and early drug interventions can be refined and scaled, the future of pancreatic cancer care may look radically different — one where the disease is caught and neutralized long before it ever becomes a diagnosis.